Silo Pharma (SILO) EBITDA Margin (2019 - 2026)
Silo Pharma (SILO) posted EBITDA Margin of 8846.44% for Q1 2026, down 102.75% sequentially from 4363.28% in Q4 2025, and down 277676.0% YoY from N/an in Q1 2025.
Silo Pharma (SILO) EBITDA Margin (2019 - 2026) Analysis & Trends
Silo Pharma has reported EBITDA Margin for 8 years, with the latest figure at 8846.44% in Q1 2026.
- Quarterly EBITDA Margin fell 277676.0% year-over-year to 8846.44% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6631.16% (up 19292.0% YoY) and the FY2025 annual result came in at 5936.95%, up 58949.0% from the prior year.
- EBITDA Margin eased to 8846.44% in Q1 2026 per SILO's latest filing, from 4363.28% in the prior quarter.
- Over five years, EBITDA Margin peaked at 2742.22% in Q2 2022 and troughed at 10059.65% in Q4 2024.
- A 5-year average of 6080.6% and a median of 5836.66% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin tumbled 360384 bps in 2024, then jumped 569637 bps in 2025.
- Over 5 years, EBITDA Margin stood at 9192.04% in 2022, then rose by 30 bps to 6455.81% in 2023, then plunged by 56 bps to 10059.65% in 2024, then jumped by 57 bps to 4363.28% in 2025, then tumbled by 103 bps to 8846.44% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 8846.44%, 4363.28%, and 6388.16% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,846.44% |
| Dec 31, 2025 | -4,363.28% |
| Sep 30, 2025 | -6,388.16% |
| Jun 30, 2025 | -6,926.77% |
| Mar 31, 2025 | -6,069.68% |
| Dec 31, 2024 | -10,059.65% |
| Sep 30, 2024 | -5,603.63% |
| Jun 30, 2024 | -5,563.24% |
| Mar 31, 2024 | -4,879.14% |
| Dec 31, 2023 | -6,455.81% |
| Sep 30, 2023 | -4,290.70% |
| Jun 30, 2023 | -6,185.77% |
| Mar 31, 2023 | -4,457.37% |
| Dec 31, 2022 | -9,192.04% |
| Sep 30, 2022 | -5,265.76% |
| Jun 30, 2022 | -2,742.22% |
| Jun 30, 2021 | -641.62% |
| Mar 31, 2021 | -1,899.81% |
| Dec 31, 2020 | -2,673.43% |
| Sep 30, 2020 | -3,431.95% |